liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease
Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Care, Clinical Pharmacology.ORCID iD: 0000-0002-2809-7591
Show others and affiliations
2006 (English)In: Alimentary Pharmacology and Therapeutics, ISSN 0269-2813, E-ISSN 1365-2036, Vol. 24, no 2, 331-342 p.Article in journal (Refereed) Published
Abstract [en]

Background: Adverse events leading to discontinuation or dose reduction of thiopurine therapy occur in 9-28% of patients with inflammatory bowel disease. Aims: To evaluate the influence of thiopurine methyltransferase status and thiopurine metabolites in a large patient population for the risk of developing adverse event. Methods: Three hundred and sixty-four patients with inflammatory bowel disease and present or previous thiopurine therapy were identified from a local database. Results: The adverse event observed in 124 patients (34%) were more common in adults than children (40% vs. 15%, P < 0.001) and in low to intermediate (≤9.0 U/mL red blood cell) than normal thiopurine methyltransferase activity (P = 0.02). Myelotoxicity developed later than other types of adverse event. An increased frequency of adverse event was observed in patients with tioguanine (thioguanine) nucleotide above 400 or methylated thioinosine monophosphate above 11 450 pmol/ 8 × 108 red blood cell. A shift to mercaptopurine was successful in 48% of azathioprine-intolerant patients and in all cases of azathioprine-induced myalgia or arthralgia. Conclusions: A pre-treatment determination of thiopurine methyltransferase status might be appropriate as patients with low to intermediate thiopurine methyltransferase activity are more prone to develop an adverse event, determination of metabolite levels can be useful in the case of an adverse event. Mercaptopurine therapy should be considered in azathioprine-intolerant patients. © 2006 The Authors.

Place, publisher, year, edition, pages
2006. Vol. 24, no 2, 331-342 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-36781DOI: 10.1111/j.1365-2036.2006.02977.xLocal ID: 32534OAI: diva2:257630
Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2013-09-03

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Lindqvist Appell, MalinAlmer, Sven
By organisation
Faculty of Health SciencesClinical PharmacologyGastroenterology and HepatologyDepartment of Endocrinology and Gastroenterology UHL
In the same journal
Alimentary Pharmacology and Therapeutics
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 46 hits
ReferencesLink to record
Permanent link

Direct link